《中国康复理论与实践》

《中国康复理论与实践》 ›› 2007, Vol. 13 ›› Issue (01): 90-91.

• 临床观察 • 上一篇    下一篇

小剂量瑞波西汀治疗精神分裂症后抑郁30例

冀伟; 何传才; 彭红波   

  1. 河南省商丘市第二人民医院,河南商丘市 476000
  • 收稿日期:2006-10-16 出版日期:2007-01-01 发布日期:2007-01-01

Effect of Low-dose Reboxitine on Post-schizophrenic Depression:30 Cases Report

  

  • Received:2006-10-16 Published:2007-01-01 Online:2007-01-01

PDF (PC)

摘要： 目的探讨用瑞波西汀(叶洛抒)治疗精神分裂症后抑郁的临床疗效和不良反应。方法30例患者均符合《中国精神障碍分类与诊断标准》第3版(CCMD-3)精神分裂症后抑郁的诊断。入组患者在原抗精神病药物剂量不变的基础上加服瑞波西汀4～8mg/d,治疗6周。分别于治疗前及治疗后2、4、6周末应用汉密顿抑郁量表(HAMD)、简明精神病评定量表(BPRS)、阴性症状量表(SANS)及副反应量表(TESS)评定疗效与副反应。结果患者HAMD评分在治疗后6周后明显下降(P<0.01);总有效率87%;精神病阴性症状亦有所减轻;不良反应轻微,多能自行缓解。结论小剂量瑞波西汀治疗精神分裂症后抑郁有较好的疗效,不良反应轻微,药物依从性好。

关键词: 精神分裂症, 精神分裂症后抑郁, 瑞波西汀, 治疗

Abstract: ObjectiveTo explore the efficacy and side-effects of reboxitine on post-schizophrenic depression.Methods30 patients with post-schizophrenic depression according CCMD-Ⅲ accepted reboxitine 4～8 mg/d in addition to antipsychotic drugs for 6 weeks. Efficacy and side-effects were determined with Hamilton Depression Scale (HAMD), Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS), Treatment Emergent Symptom Scale (TESS) before and 2, 4, 6 weeks after treatment. ResultsThe score of HAMD were obviously improved after the treatment(P<0.01), as well as that of negative psychotic symptoms in BPRS and TESS. Slight symptoms that may be associated to the Reboxitine were obvioused seldom, and all recovered without any treating. ConclusionLow-dose rebositine is effective on post-schizophrenic depression with few side-effects and good compliance.

Key words: schizophrenia, post-schizophrenic depression, reboxitine, treatment